Metastatic breast cancer epidemiology and management with a focus on taxanes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Donovan D;Donovan D
  • Source:
    Clinical journal of oncology nursing [Clin J Oncol Nurs] 2013 Feb; Vol. 17 Suppl, pp. 5-8.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Oncology Nursing Press Country of Publication: United States NLM ID: 9705336 Publication Model: Print Cited Medium: Internet ISSN: 1538-067X (Electronic) Linking ISSN: 10921095 NLM ISO Abbreviation: Clin J Oncol Nurs
    • Publication Information:
      Original Publication: Pittsburgh, PA : Oncology Nursing Press, [1997-
    • Subject Terms:
      Neoplasm Metastasis*; Antineoplastic Agents, Phytogenic/*therapeutic use ; Breast Neoplasms/*drug therapy ; Taxoids/*therapeutic use; Breast Neoplasms/pathology ; Female ; Humans
    • Abstract:
      Although considerable treatment advances have been made since the early 2000s, metastatic breast cancer (MBC) continues to provide challenges for patients and healthcare providers. The responsibilities of nurses regarding the management of MBC are extensive. Among other things, nurses must provide patient education, understand treatment administration, and have the ability to perform patient assessments, as well as identify and manage symptoms. The taxanes paclitaxel, docetaxel, and nab-paclitaxel are a class of microtubule-stabilizing agents that are highly active against MBC but have many differences among them (e.g., formulation, administration, efficacy, tolerability profiles). Understanding those differences will aid in improving the overall patient experience. This supplement provides a historical overview of taxanes, examines the differences in their administration, and defines their efficacy and safety profiles and effects on patient quality of life. In addition, methods for assessing taxane-induced neuropathy are discussed from the nursing perspective, and treatment considerations for older adult patients with MBC are provided.
    • Accession Number:
      0 (Antineoplastic Agents, Phytogenic)
      0 (Taxoids)
    • Publication Date:
      Date Created: 20130131 Date Completed: 20131118 Latest Revision: 20130130
    • Publication Date:
      20240829
    • Accession Number:
      10.1188/13.CJON.S1.5-8
    • Accession Number:
      23360697